Reduction of femoral artery bleeding post catheterization using a collagen enhanced fibrin sealant

Falstrom, Jeanne K.; Goodman, Norman C.; Ates, Gursel; Abbott, Robert D.; Powers, Eric R.; Spotnitz, William D.

doi:10.1002/(sici)1097-0304(199705)41:1<79::aid-ccd18>3.0.co;2-l

Cited by 13 publications

(1 citation statement)

References 42 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These efforts included work in a variety of surgical disciplines including breast [9, 13, 14, 16, 17, 32, 36], cardiovascular [11, 26, 27, 30, 33], gastrointestinal [10], head and neck [22, 35], hepatic [12, 20], neuro- [29], orthopedic [21, 37, 40, 41], pediatric [12], noncardiac thoracic [25, 30, 31, 33, 34], and vascular surgery [15, 18, 19, 23, 24, 38, 39]. This body of work emphasized the evolving versatility of fibrin sealant because it is capable of causing blood to clot, creating a sealing barrier, and gluing tissues together.…”

Section: Introductionmentioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

Self Cite

View full text Add to dashboard Cite

Background. Fibrin sealant became the first modern era material approved as a hemostat in the United States in 1998. It is the only agent presently approved as a hemostat, sealant, and adhesive by the Food and Drug Administration (FDA). The product is now supplied as patches in addition to the original liquid formulations. Both laboratory and clinical uses of fibrin sealant continue to grow. The new literature on this material also continues to proliferate rapidly (approximately 200 papers/year). Methods. An overview of current fibrin sealant products and their approved uses and a comprehensive PubMed based review of the recent literature (February 2012, through March 2013) on the laboratory and clinical use of fibrin sealant are provided. Product information is organized into sections based on a classification system for commercially available materials. Publications are presented in sections based on both laboratory research and clinical topics are listed in order of decreasing frequency. Results. Fibrin sealant remains useful hemostat, sealant, and adhesive. New formulations and applications continue to be developed. Conclusions. This agent remains clinically important with the recent introduction of new commercially available products. Fibrin sealant has multiple new uses that should result in further improvements in patient care.

show abstract

Section: Introductionmentioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

Self Cite

View full text Add to dashboard Cite

show abstract

Percutaneous arterial closure in severely scarred groins: A technical note

Winter

Khalighi

Claussen

et al. 1998

Cathet. Cardiovasc. Diagn.

View full text Add to dashboard Cite

Efficacy of a novel hemostatic agent in animal models of impaired hemostasis

Prior¹,

Powers²,

DeLustro³

2000

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

This study evaluated the efficacy of a novel sprayable hemostat under both normal conditions and those of compromised coagulation. CoStasistrade mark Surgical Hemostat ("CoStasis"), containing collagen, thrombin, and autologous plasma, was compared to Instattrade mark collagen sponge, an investigational fibrin sealant, and a no treatment control, for the ability to control bleeding in a rabbit kidney model. Hemostatic performance was determined by time to hemostasis and blood loss in a nonsurvival, randomized, in vivo bleeding rabbit kidney model. Under conditions of normal coagulation, as well as aspirin and heparin treatment, hemostasis was achieved faster with CoStasistrade mark than with Instattrade mark and fibrin sealant. With the exception of the time to hemostasis using Instattrade mark sponge in heparinized rabbits, all differences were statistically significant (p < 0.03, Wilcoxon). Blood loss, where measured, was lower with CoStasistrade mark than with the other hemostats under the three coagulation conditions. Statistical significance, (p < 0.03, Wilcoxon), was achieved with all comparisons except with fibrin sealant in aspirin treated animals. The combination of collagen, thrombin, and autologous plasma used in CoStasis, can achieve significantly faster hemostasis than the conventional atraumatic hemostats, collagen sponge, and fibrin sealant under normal conditions and conditions of impaired hemostasis.

show abstract

Reduction of femoral artery bleeding post catheterization using a collagen enhanced fibrin sealant

Cited by 13 publications

References 42 publications

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Percutaneous arterial closure in severely scarred groins: A technical note

Efficacy of a novel hemostatic agent in animal models of impaired hemostasis

Contact Info

Product

Resources

About